5-MeO-T-NBOMe
5-MeO-T-NBOMe, also known as 5MT-NBOMe or NBOMe-5-MeO-T, is a psychedelic of the tryptamine family related to the 25-NB drugs. It has been sold online as a designer drug.
5-MeO-T-NBOMe is said to produce hallucinogenic effects in humans.
Pharmacology
Pharmacodynamics
5-MeO-T-NBOMe is a serotonin 5-HT2 receptor agonist and produces the head-twitch response in rodents. However, compared to 25I-NBOMe, the drug is much less potent in producing the head-twitch response and produces a much weaker maximal response. 5-MeO-T-NBOMe is many times less potent than comparable phenethylamines such as 25C-NBOMe, but is still a reasonably potent and effective partial agonist for the 5-HT2 family of serotonin receptors. A number of related compounds have also been developed, and in contrast to the phenethylamine counterparts the meta-substituted benzyl derivatives are in many cases more potent than the ortho-substituted benzyl compounds.
Chemistry
Analogues of 5-MeO-T-NBOMe include N-benzyltryptamine, 4-HO-NBnT, 5-MeO-NBnT, 5-MeO-T-NB3OMe, 5-MeO-NBpBrT, 5-MeO-N-DEAOP-NMT, and NEtPhOH-THPI, among others. It also shares structural similarities with pertines like oxypertine.
History
5-MeO-T-NBOMe was described by David E. Nichols and colleagues in 2015. It was encountered online as a novel designer drug in 2023.
Canada
5-MeO-T-NBOMe is not a controlled substance in Canada as of 2025.
5-MeO-T-NBOMe is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.